“…While some studies assessed the resilience of EBC patients during active oncology treatment [ 25 , 26 , 27 , 29 , 35 ], others assessed resilience among BC survivors [ 17 , 28 , 31 , 32 , 35 , 36 ], and few combined early and metastatic BC patients [ 15 , 16 , 24 , 37 ]. Furthermore, very few studies were designed with a control group [ 29 , 32 , 33 , 35 , 38 ], or included a BC group that consisted of early and metastatic BC patients. Taking into account potential confounding factors of the BC treatment trajectory and survivorship, it was difficult to conclude what the direct impact of BC diagnosis on resilience levels is.…”